Biotech Startups

GenAIRx develops AI technology to accelerate the discovery and development of specialty medicines. The company serves pharmaceutical and biotech organizations seeking to improve drug development timelines and outcomes.

1 investor

GenBody manufactures rapid diagnostic test kits, fluorescence immunoassay kits, and analysis equipment for human and veterinary use, including tests for infectious diseases, drug screening, and chronic conditions. The company also produces laboratory animals for research purposes.

1 investor

GenDx develops molecular diagnostic reagents, software, and services for transplant patient outcomes. Operating globally since 2005, the company serves the healthcare and diagnostics industry with specialized tools for transplant diagnostics.

1 investor

Gene Solutions is a biotechnology company that develops genetic testing solutions using Next-Generation Sequencing and artificial intelligence for reproductive health, clinical oncology, and multi-cancer screening. The company serves healthcare providers and patients seeking precision medicine through advanced genomic profiling and early cancer detection.

1 investor

Gene BioSystems manufactures ready-to-use qPCR reagent kits for quantitative PCR analysis across major real-time PCR systems. The products are designed for research laboratories and diagnostic facilities requiring molecular biology testing reagents.

1 investor

A biotech company offering gene expression analysis tools for blood-based biomarker detection across multiple cancer types. The company develops molecular signatures and liquid biopsy solutions for biopharma, diagnostics, and CRO partners.

1 investor

Genedrive Diagnostics develops and commercialises a rapid point-of-care pharmacogenetic testing platform that detects genetic variants to guide personalised medicine decisions in emergency healthcare. The UK-based company's tests help clinicians tailor drug choices based on a patient's genetics.

1 investor

GeneDx provides advanced genetic testing and clinical interpretation services to help clinicians diagnose rare and inherited genetic disorders, with AI-driven genomic intelligence that supports patient care decisions and accelerates research and drug discovery.

1 investor

GeneLancet develops proprietary LgRNA technology for precise gene editing, with applications in CRISPR polymerase-directed therapies targeting neurodegenerative diseases and cancers with unmet medical needs.

1 investor

GeneNeer develops advanced gene-editing platforms to accelerate the development of crop seeds with improved yield, growth, and nutritional value for the agricultural supply chain. The company uses proprietary methods offering superior efficiency, precision, speed and affordability compared to existing CRISPR and similar technologies.

1 investor

Genenta Science is a clinical-stage biotechnology company developing Temferon, a hematopoietic stem cell-based gene therapy platform for treating cancer. The company is publicly traded on Nasdaq under the ticker GNTA.

1 investor

1 investor

Generable develops statistical and computational models for drug development and healthcare decision-making, leveraging Bayesian methods and probabilistic modeling. The company serves pharmaceutical and biotech organizations in developing safer and more efficient therapeutic interventions.

1 investor

General Biotechnologies manufactures peptide therapeutics by genetically programming edible microbes to synthesise molecules, aiming to produce them at lower cost. It focuses on reviving clinically proven but discontinued off-patent peptides as low-cost oral drugs, including an oral GLP-1, and partners with pharma companies to bring shelved assets back as oral formulations.

1 investor

Generate Life Sciences was a reproductive, newborn stem cell, and genetic services company offering products and services to help families grow and protect their families. It has been acquired by CooperSurgical.

1 investor

A biotech-focused investment firm that creates and backs companies in the future of medicine.

1 investor

Adapsyn Bioscience is a biotechnology company that uses proprietary algorithms and artificial intelligence to analyze genomic and metabolomic data from microbes in order to discover novel small molecule natural product drug candidates.

1 investor

GeneTech provides non-invasive prenatal testing (NIPT) using fetal cell-free DNA from maternal blood, along with clinical laboratory testing services, offered to certified medical institutions in Japan. It introduced NIPT in Japan in 2013 and runs a domestic analysis lab, serving pregnant patients and their families through partner hospitals.

1 investor

Genetica is an artificial intelligence-powered genetic testing company that analyzes hundreds of genes to provide scientific insights about physical traits, behavior, intelligence, and health risks for Asian populations. The company partners with leading genome sequencing organizations and aims to optimize personal development plans and protect individual and family health.

1 investor

Geneticure offers a patented genetic test that uses a cheek-swab DNA sample, analyzing 17 genotypes across 11 genes to recommend personalized hypertension (blood pressure) treatment plans. The test helps doctors prescribe effective treatments by assessing the responsiveness of the patient's cardiac, vascular, and renal systems, reducing trial-and-error prescribing.

1 investor

GENEWIZ provides sequencing, synthesis, and molecular biology services for research, clinical, and therapeutic applications, serving academic institutions, biotech companies, and pharmaceutical organizations.

1 investor

Geneyx offers a genomic data analysis platform for secondary and tertiary interpretation of NGS data, including exome, whole genome sequencing, and gene panels, with AI/ML-driven variant interpretation, automated annotation, and customizable reporting. It serves genetics labs, life-science companies, clinical researchers, and research institutes worldwide, integrating with LIMS and existing bioinformatic pipelines.

1 investor

Genica develops biological agricultural inputs (bioinsumos) such as biofertilizers, biological fungicides, and nematicides based on microorganisms and organic molecules to improve crop productivity. The company uses bioprospecting, molecular techniques, and bioinformatics to create products for farmers, serving the agriculture sector in Brazil.

1 investor

GenieBiome (G-NiiB) develops microbiome-modifying technology and therapeutic candidates supported by clinical trials, using next-generation sequencing. The company focuses on treating human diseases through microbiome-based solutions.

1 investor